The most common primary brain tumors in adults are gliomas, among which the incurable glioblastoma multiforme (GBM) is notorious for its highly invasive and aggressive behavior. Currently, no efficacious treatments are available. One promising approach is to modulate the immune system to specifically target and destroy tumor cells. In this context, we evaluated dendrimers and the multi-epitope proteins ZEBRA-mad1/-mad2 as vaccine vector candidates in vitro. We investigated their uptake by bone marrow derived dendritic cells (BMDCs) and monitored antigen presentation to specific CD4 and CD8 T cells from TCR transgenic mice by measuring T cell clonal expansion and effector functions. We demonstrated that the dendrimers and the ZEBRA-mad1/-mad2 proteins could efficiently serve as a delivery platform of antigens in vitro as there was efficient uptake and presentation by the BMDCs, inducing high T cell proliferation. Furthermore, T cells that recognized the epitopes presented by ZEBRA-mad1 also expressed effector cytokines. Overall, these two vectors are promising candidates as an antigen delivery system for cancer vaccines, but their efficacy in stimulating anti-tumor immune responses has to be confirmed in vivo.